|
|
 |
|
|
faculty profile |
|
|
| Dr. Pinku Mukherjee |
| Irwin Belk Distinguished Scholar in Cancer Research |
 |
Department: Biology |
|
Office: Woodward Hall 490C |
|
Office Hours: |
|
Email: pmukherj@uncc.edu |
|
Phone: 704-687-5459 |
|
Personal Homepage |
|
|
|
 |
|
|
|
|
|
Research Description:
Mukherjee comes to UNC Charlotte from the Mayo Clinic in Scottsdale, Ariz., where she was an Associate Professor of Immunology and Director of the Cellular Immunology Laboratory. Mukherjee’s research focuses on the development of efficient and targeted immune modulating therapies delivered directly to the tumor site in breast and pancreatic cancers. |
|
|
Recent Publications:
Teresa L. Tinder, Durai B. Subramani, Gargi D. Basu, Judy M. Bradley, Jorge Schettini, Arefayene Million, Todd Skaar, and Pinku Mukherjee (2008). MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma. J Immunology, 181: 3116 – 3125
Pinku Mukherjee, Gargi D. Basu, Teresa L. Tinder, Durai B. Subramani, Judy M. Bradley, Million Arefayene, Todd Skaar, and Giovanni De Petris (2008) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition, Journal of Immunology (in press).
Basu, G.D., Liang, W., Tinder, T., Stephan, D., Wegener, L.T., Conley, C.R., and Mukherjee, P. (2007) A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Research. 8: 69-75 (Breast Cancer Net News Release, Article highlighted as highly accessed)
Mukherjee, P, Pathangey, L.B, Bradley, J.B, Tinder, T.L, Basu, G.B, Akporiaye, E.T, and Gendler, S.J. (2007). MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine. 25: 1607-1618
Basu, G.D., Tinder, T.L., Bradley, J.M., Tu, T., Hattrup, C.L., Pockaj, B.A., and Mukherjee, P. (2006) Cyclooxygenase 2 inhibitor enhances the efficacy of a breast cancer vaccine: role of Indoleamine 2,3, Dioxygenase. J Immunology. 177:2391-2402.
Basu, G.D., Pathangey, L.B., Tinder, T.L., Gendler, S.J., and Mukherjee, P. (2005) Mechanisms underlying to growth inhibitory effects of COX-2 inhibitor in human breast cancer cells. Breast Cancer Research 7:R422-R435. (Breast Cancer Net News Release).
Theodore H. Lindsay, Beth M. Jonas, Molly A. Sevcik, Kazufumi Kubota, Kyle G. Halvorson, Joseph R. Ghilardi, Micheal A. Kuskowski, Edward B. Stelow, Pinku Mukherjee, Sandra J. Gendler, Gilbert Y. Wong, Patrick W. Mantyh (2005) Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain, 119:233-246 (Cover).
Mukherjee, P., Tinder, T.L., Basu, G.D., Pathangey, L.B., Chen, L. and Gendler, S.J. (2004) Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. Breast Disease, 20:53-63. (Breast Cancer Net News Release).
Mukherjee, P., Tinder, T.L., Basu, G.D., and Gendler, S.J. (2004) MUC1 (CD227) interacts with Ick tyrosine kinase in Jurkat lymphoma cells and normal T cells. Journal of Leukocyte Biology, 77:90-99.
Basu, G.D., Pathangey, L.B., Tinder, T.L., LaGioia, M. Gendler, S.J., and Mukherjee, P. (2004) Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Molecular Cancer Research, 2:532-642. (Cover) (American Association for Cancer Research Press Release).
|
|
|
Research Areas:
Breast Cancer
Immunotherapy
Pancreas Cancer
Tumor Immunology
|
|
|
|
